20. CAR-T and Immune checkpoint blockade (ICB) are two breakthroughs in recent years for tumor immunotherapy. Which statement concerning these two approaches is NOT CORRECT? (A) CAR-T approach bypasses the requirement of recognition of MHC-peptide and 2 signals to activate antigen-specific T cells (B) The ICB approved for treating cancer patients is to block molecules that transduce inhibitory signals in T cells, not in antigen-presenting cells (C) CAR-T and ICB both work for solid tumors and leukemia efficiently (D) The mechanisms for anti-CLT4 and anti-PD-1 ICBs are different; therefore, there is increased therapeutic activity when combining both treatments